Tracking Health and Wellness Applications of Brain Science

neurotechnologies

On cognitive reframing and biases, stress, mental health tech, Aduhelm backlash, Britney Spears, and more

by Leave a Comment

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing this time nine sci­en­tif­ic reports and indus­try devel­op­ments to help pro­mote life­long brain and men­tal health.

#1. To low­er stress lev­els and improve prob­lem-solv­ing, prac­tice cog­ni­tive refram­ing instead of venting

“… vent­ing like­ly doesn’t soothe anger as much as aug­ment it. That’s because encour­ag­ing peo­ple to act out their anger makes them relive it in their bod­ies, strength­en­ing the neur­al path­ways for anger and mak­ing it eas­i­er to get angry the next time around. Stud­ies on vent­ing anger (with­out effec­tive feed­back), whether online or ver­bal­ly, have also found it to be gen­er­al­ly unhelp­ful … To get out of that, you can ask the per­son to step back and help you reframe your expe­ri­ence by ask­ing, “How should I think about this dif­fer­ent­ly?” or “What should I do in this situation?”

#2. Head­space and Gin­ger merge to expand and scale up dig­i­tal men­tal health

“The new com­pa­ny would find it push­ing well beyond its cur­rent mind­ful­ness focus to, “pro­vide the full spec­trum of proven, effec­tive vir­tu­al sup­port – from mind­ful­ness and med­i­ta­tion, to text-based behav­ioral health coach­ing, to video-based ther­a­py and psy­chi­a­try – for all types of patient populations.”

Ambi­tious move!

#3. How to read, under­stand and write great med­ical research

12 good tips for stu­dents and every­one else

#4. Vet­er­ans Affairs won’t cov­er Biogen’s new “Alzheimer’s drug” giv­en con­cerns over safe­ty and lack of evidence

Their inde­pen­dent review con­cludes that “giv­en the lack of evi­dence of a robust and mean­ing­ful clin­i­cal ben­e­fit and the known safe­ty sig­nal, we rec­om­mend against offer­ing this agent to patients with Alzheimer’s demen­tia (mild or oth­er­wise) or mild cog­ni­tive impairment.”

#5. Alzheimer’s & Demen­tia researchers chal­lenge FDA’s approval of Aduhelm giv­en lack of evi­dence for beta-amy­loid as a marker

A strong call to “learn how this reg­u­la­to­ry fail­ure occurred and to ensure that it doesn’t occur again”

#6. Debunk­ing four myths about deci­sion-mak­ing capac­i­ty to keep Brit­ney Spears and oth­ers safe

Address­ing the ongo­ing con­tro­ver­sy about con­ser­va­tor­ships, a USC Pro­fes­sor of Law, Psy­chol­o­gy, and Psy­chi­a­try shares a great arti­cle to debunk these all-too-com­mon myths

#7. Study exam­ines com­mon cog­ni­tive bias­es (have you tried this brain teas­er?) and ways to mit­i­gate them

If you have not encoun­tered the “Lin­da brain teas­er” before, please give it a try! If you have, you’ll enjoy the new paper titled Tver­sky and Kahneman’s Cog­ni­tive Illu­sions: Who Can Solve Them, and Why?

#8. Inte­grat­ing music, move­ment and stroke reha­bil­i­ta­tion, MedRhythms rais­es $25M to devel­op and com­mer­cial­ize dig­i­tal therapeutic

Fas­ci­nat­ing approach to gait training.

#9. Neu­rotech start-up Paradromics rais­es $20M to address brain-relat­ed dis­or­ders via next-gen brain-com­put­er interfaces

Neu­ralink vs. Paradromics vs. non-inva­sive plat­forms — quite a stim­u­lat­ing space to track

 

Wish­ing you and yours a hap­py and healthy back-to-school and month of September,

The Sharp­Brains Team

Headspace and Ginger merge to expand and scale up digital mental health

by Leave a Comment

Head­space and Gin­ger are merg­ing to form Head­space Health (TechCrunch):

Med­i­ta­tion app Head­space this morn­ing announced plans to merge with on-demand men­tal health ser­vice Gin­ger. Bar­ring unfore­seen reg­u­la­to­ry road­blocks, the two com­pa­nies will com­bine to form Head­space Health. The new orga­ni­za­tion would sport a com­bined val­ue of $3 bil­lion and a head­count of more than 800.

The merg­er comes dur­ing accel­er­at­ed usage of both par­ties, as a seem­ing­ly end­less pan­dem­ic has put a strain on men­tal health across the globe and many have turned to vir­tu­al solu­tions to address the grow­ing prob­lem. [Read more…] about Head­space and Gin­ger merge to expand and scale up dig­i­tal men­tal health

Integrating music, movement and stroke rehabilitation, MedRhythms raises $25M to develop and commercialize digital therapeutic

by Leave a Comment

MedRhythms rais­es 25m to get patients back in tune after a stroke (TechCrunch):

MedRhythms secured $25 mil­lion in Series B fund­ing to advance its dig­i­tal ther­a­py plat­form aimed at mea­sur­ing and improv­ing someone’s abil­i­ty to walk after they have expe­ri­enced a neu­ro­log­ic injury or dis­ease … Com­pa­ny co-founder and CEO Bri­an Har­ris was a neu­ro­log­ic music fel­low at Spauld­ing Reha­bil­i­ta­tion Hos­pi­tal in Boston, treat­ing peo­ple with stroke and brain deficits with music. He began get­ting ques­tions from patients and fam­i­lies on how they could access sim­i­lar care out­side of the hos­pi­tal. Not see­ing a suit­able alter­na­tive, he start­ed MedRhythms with entre­pre­neur Owen McCarthy in 2016. [Read more…] about Inte­grat­ing music, move­ment and stroke reha­bil­i­ta­tion, MedRhythms rais­es $25M to devel­op and com­mer­cial­ize dig­i­tal therapeutic

Update on the aducanumab (Aduhelm) saga, retirement, financial advice, cognitive health, excessive worrying, neurotech, and more

by

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, pro­vid­ing this time a sum­ma­ry of the saga around the FDA approval of adu­canum­ab (Aduhelm) as a sup­posed treat­ment for Alzheimer’s Dis­ease, plus a range of time­ly research find­ings and resources for life­long brain health.

First, below are some key reads to nav­i­gate “prob­a­bly the worst drug approval deci­sion in recent U.S. his­to­ry” — Dr. Aaron Kessel­heim, the Pro­fes­sor of Med­i­cine at Har­vard Med­ical School who resigned rom the FDA Advi­so­ry Com­mit­tee in protest.

#1. Grow­ing back­lash against the FDA approval of unproven Alzheimer’s treat­ment Aduhelm, by Bio­gen:

“The Insti­tute for Clin­i­cal and Eco­nom­ic Review (ICER) believes that the FDA, in approv­ing adu­canum­ab (Aduhelm by Bio­gen) for the treat­ment of Alzheimer’s dis­ease, has failed in its respon­si­bil­i­ty to pro­tect patients and fam­i­lies from unproven treat­ments with known harms.”

#2. First, do no harm? Six rea­sons to approach anti-amy­loid drug Aduhelm cau­tious­ly, if at all:

“The FDA’s approval of Aduhelm rais­es more ques­tions and cre­ates more prob­lems than a new drug approval should. It’s time for gov­ern­men­tal, pro­fes­sion­al, and advo­ca­cy enti­ties to step in where Bio­gen and the FDA have failed and explain to patients, care­givers, and clin­i­cians how this drug is not the “new day” in the fight against Alzheimer’s dis­ease and needs to be approached cau­tious­ly, if at all.” — Dr. Sam Gandy, Pro­fes­sor of Neu­rol­o­gy and Psy­chi­a­try at the Icahn School of Med­i­cine at Mount Sinai, where he holds the Mount Sinai Chair in Alzheimer’s Research

#3. Can the con­tro­ver­sial FDA approval of Aduhelm back­fire and delay the dis­cov­ery of actu­al Alzheimer’s treat­ments? (Yes, it can):

“In short, while the amy­loid hypoth­e­sis has fal­tered, the approval of adu­canum­ab, which is based pri­mar­i­ly on this the­o­ry, sug­gests that the the­o­ry may once again dom­i­nate research, and could reduce the chances of find­ing more promis­ing treat­ments. For exam­ple, tau pro­tein, which also accu­mu­lates in the brains of Alzheimer’s patients — long before the amy­loid pro­tein does — has been shown to be close­ly asso­ci­at­ed with the cog­ni­tive impair­ment result­ing from the dis­ease … we must not inter­rupt research on bio­mark­ers and new ther­a­peu­tic approaches.”

#4. US Sen­a­tor Joe Manchin calls for a new FDA Com­mis­sion­er to replace cur­rent (act­ing) one who “has repeat­ed­ly ignored pub­lic health con­cerns and shown a dere­lic­tion of duty” over opi­oids and adu­canum­ab:

“I write today con­cern­ing the lack of per­ma­nent lead­er­ship at the Food and Drug Admin­is­tra­tion (FDA), and the con­tin­ued tenure of Dr. Janet Wood­cock as inter­im com­mis­sion­er. Just last week, the FDA grant­ed approval for Aduhelm (adu­canum­ab), a treat­ment for Alzheimer’s, despite its advi­so­ry pan­el vot­ing near­ly unan­i­mous­ly against its approval, with no pan­el mem­ber vot­ing in favor of approval”

(Let’s hope some­thing use­ful emerges from this very unhealthy FDA deci­sion. Quite dis­turb­ing, though, to notice the links between the opi­oid epi­dem­ic and the recent Aduhelm approval.)

#5. Health payers–including Medicare and Point32Health–to ques­tion Aduhelm pric­ing and its “rea­son­able and nec­es­sary” use:

“Under the broad label that FDA approved, the drug is avail­able to all Alzheimer’s patients, and the agency did not place lim­its on treat­ment dura­tion sug­gest­ing that patients could remain on the drug indef­i­nite­ly. We are trou­bled by reports that those fac­tors could lead the drug to com­mand “some­where between” the $37 bil­lion we cur­rent­ly spend on Medicare Part B and the $90 bil­lion we cur­rent­ly spend on Medicare Part D. This lev­el of poten­tial new spend­ing, par­tic­u­lar­ly for just one prod­uct with lim­it­ed evi­dence of clin­i­cal effi­ca­cy thus far, tests the program’s resiliency.”

The stakes could­n’t be higher.

Now let’s review oth­er impor­tant devel­op­ments in June.

#6. Debate: What is the role of finan­cial advi­sors and plat­forms in detect­ing and address­ing cog­ni­tive decline among old­er clients?:

” … big do-it-your­self invest­ing and trad­ing venues like Van­guard Group, Fideli­ty Invest­ments and Charles Schwab Corp. are strength­en­ing some of the ways they detect pos­si­ble signs of decline. Among oth­er things, all three firms check for clients’ dif­fi­cul­ty nav­i­gat­ing secu­ri­ty pro­to­cols or need for fre­quent pass­word resets. In such cas­es, a des­ig­nat­ed fam­i­ly mem­ber might be informed.

Van­guard also checks client-call record­ings for keywords—such as “con­fused” and “dementia”—that might sig­nal trouble.”

#7. Study in Chi­na finds that retire­ment may accel­er­ate cog­ni­tive decline, even for those with sta­ble income:

“While retire­ment schemes like the 401(k) and sim­i­lar pro­grams in oth­er coun­tries are typ­i­cal­ly intro­duced to ensure the wel­fare of aging adults, our research sug­gests they need to be designed care­ful­ly to avoid unin­tend­ed and sig­nif­i­cant adverse con­se­quences. When peo­ple con­sid­er retire­ment, they should weigh the ben­e­fits with the sig­nif­i­cant down­sides of a sud­den lack of men­tal activ­i­ty. A good way to ame­lio­rate these effects is to stay engaged in social activ­i­ties and con­tin­ue to use your brains in the same way you did when you were working.

In short, we show that if you rest, you rust.”

#8. The explo­sion of men­tal health apps rais­es sub­stan­tial opportunities–and tough ques­tions:

“Dig­i­tal men­tal health can be viewed as a way to extend the men­tal resources that we have,” said David Mohr, who directs the Cen­ter for Behav­ioral Inter­ven­tion Tech­nolo­gies at the North­west­ern Uni­ver­si­ty Fein­berg School of Med­i­cine. A step-care mod­el, for exam­ple, would allow patients with milder symp­toms to be treat­ed via tech­nol­o­gy while reserv­ing in-per­son care for patients who need some­thing more.

#9. Pre­scrip­tion soft­ware firm Pear Ther­a­peu­tics to go pub­lic via $1.6 bil­lion SPAC deal, har­ness­ing 3 FDA-autho­rized prod­ucts and 14 can­di­dates:

“Pear is one of nine com­pa­nies invit­ed to par­tic­i­pate in the U.S. Food and Drug Administration’s (FDA) Pre­cer­ti­fi­ca­tion Pilot Pro­gram. Pear has devel­oped and com­mer­cial­ized the first three FDA-autho­rized PDTs, has 14 prod­uct can­di­dates, and is scal­ing its plat­form for third-par­ty prod­uct dis­tri­b­u­tion oppor­tu­ni­ties. The Company’s three FDA-autho­rized prod­ucts, reSET®, reSET‑O® and Som­ryst®, address large mar­ket oppor­tu­ni­ties with more than 20 mil­lion patients suf­fer­ing from sub­stance and opi­oid use dis­or­ders and more than 30 mil­lion from chron­ic insom­nia, in the U.S. alone, respectively.”

#10. Don’t wor­ry, be hap­py: How exces­sive wor­ry­ing may influ­ence the rate of neu­rode­gen­er­a­tion:

“(Research find­ings) sug­gest that cog­ni­tive func­tion may need to be mon­i­tored close­ly in indi­vid­u­als with affec­tive dis­or­ders, as these indi­vid­u­als may be at par­tic­u­lar risk of greater cog­ni­tive decline.”

#11. Smarter cars are com­ing soon … : Eye-track­ing pio­neer Smart Eye acquires MIT spin-off Affec­ti­va to aug­ment dri­ver mon­i­tor­ing sys­tems and more

#12. And, much more: DARPA-fund­ed non­sur­gi­cal neu­rotech­nolo­gies push the fron­tier of brain-machine interfaces

Final­ly, a quick cog­ni­tive exer­cise. Giv­en the uni­ver­sal beau­ty of math, you don’t need to speak Span­ish to try this quick teas­er: Brain teasers en español: ¿cuál es el número que fal­ta en el cuar­to triángulo?

Wish­ing you a hap­py and healthy summer,

The Sharp­Brains Team

Eye-tracking pioneer Smart Eye acquires MIT spin-off Affectiva to augment driver monitoring systems and more

by

Emo­tion-detec­tion soft­ware start-up Affec­ti­va acquired for $73.5M (TechCrunch):

Smart Eye, the pub­licly trad­ed Swedish com­pa­ny that sup­plies dri­ver mon­i­tor­ing sys­tems for a dozen automak­ers, has acquired emo­tion-detec­tion soft­ware start­up Affec­ti­va for $73.5 mil­lion in a cash-and-stock deal. [Read more…] about Eye-track­ing pio­neer Smart Eye acquires MIT spin-off Affec­ti­va to aug­ment dri­ver mon­i­tor­ing sys­tems and more

On building better brains at any age, treating Depression vs. Dementia, emerging neurotechnologies, psychedelics, and more

by

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing eleven new research find­ings and inno­v­a­tive resources for life­long cog­ni­tive and brain health.

#1. Debate: Are depres­sion and demen­tia two sides of the same coin? And, if they are, how to best approach treatment?

#2. Either way, the ear­li­er the bet­ter, but it’s nev­er too late: New book out­lines the five lifestyle pil­lars to “build a bet­ter brain at any age”

#3. “If I were a car­di­ol­o­gist eval­u­at­ing a patient’s chest pain, for instance, I would speak with the patient, but then I would lis­ten to their heart and mea­sure their pulse and blood pres­sure. I might order an elec­tro­car­dio­gram or a car­diac stress test, tools that weren’t avail­able a cen­tu­ry ago. Because I’m a psy­chi­a­trist, how­ev­er, I eval­u­ate patients in pre­cise­ly the same way that my pre­de­ces­sors did in 1920…” Read­ing Our Minds: New book issues strong call to action to mod­ern­ize psychiatry

#4. Very time­ly effort by Well­come in the UK: Com­pre­hen­sive research review iden­ti­fies most promis­ing inter­ven­tions to boost work­place men­tal health

#5. “As we enter the sec­ond year of the pan­dem­ic, so many peo­ple are strug­gling and seek­ing men­tal health sup­port. Wysa is an exam­ple of how tech­nol­o­gy is help­ing mil­lions of peo­ple access every­day men­tal health sup­port and self-care tools with­out being gat­ed by a clin­i­cal diag­no­sis.” — Dr. Pankaj Jeth­wani, Exec­u­tive Vice Pres­i­dent at W Health Ven­tures. Arti­fi­cial Intel­li­gence (AI)-enabled chat­bot Wysa rais­es $5.5M to broad­en access to men­tal health support

#6. Study: Social media and gen­er­al tech engage­ment not found to “fry” teenagers’ brains

#7. Akili Inter­ac­tive Labs rais­es $160M in equi­ty and debt to trans­form cog­ni­tive health­care via pre­scrip­tion videogame treat­ments. A nice way to cel­e­brate Akil­i’s 10th anniver­sary … they are tar­get­ing ADHD first (now kids, lat­er teens and adults), to be fol­lowed by treat­ments for a range of cog­ni­tive dis­or­ders relat­ed to depres­sion, Mul­ti­ple Scle­ro­sis, Autism, “Covid-Fog” and more.

#8. Study: High­er men­tal well­be­ing (in 2016) seen to low­er health­care costs (in 2017). We still have time to invest in pub­lic men­tal well­be­ing in 2021.

#9. Teladoc Health, hav­ing acquired Livon­go and myS­trength, launch­es inte­grat­ed men­tal health ser­vice for the work­place. “The announce­ment comes as more than half of peo­ple with men­tal health con­cerns report that they do not know where to start when get­ting care, high­light­ing the impor­tance of the dig­i­tal front door myS­trength Com­plete will pro­vide…” This is indeed a very com­mon pain point accord­ing to our own research, so good to see the quite com­pre­hen­sive & per­son­al­ized approach.

#10. Cumu­lus Neu­ro­science rais­es $8.3M to devel­op EEG-based wire­less ‘Fit­bit for the brain’ — Fas­ci­nat­ing to see the major role of the Demen­tia Dis­cov­ery Fund, in a bid to accel­er­ate clin­i­cal tri­als and poten­tial therapies.

#11. Last but not least, a very promis­ing clin­i­cal appli­ca­tion of psy­che­delics: Study finds MDMA-assist­ed ther­a­py to be safe and high­ly effec­tive to treat severe PTSD. “The Nature authors spec­u­late that MDMA-assist­ed ses­sions pro­duce a “win­dow of tol­er­ance,” in which patients are able to revis­it trau­mat­ic mem­o­ries, with less shame and anger, and with­out being over­whelmed by PTSD symptoms.”

Wish­ing you a healthy Memo­r­i­al Week­end and month of June,

The Sharp­Brains Team